These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10861648)

  • 1. Profound suppression of hepatitis B virus replication with lamivudine.
    Lai CL; Yuen MF
    J Med Virol; 2000 Jul; 61(3):367-73. PubMed ID: 10861648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver disease-significant improvement with lamivudine.
    Leung N
    J Med Virol; 2000 Jul; 61(3):380-5. PubMed ID: 10861650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical potential of emerging new agents in hepatitis B.
    Farrell GC
    Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].
    Yao GB; Wang BE; Cui ZY; Yao JL; Zeng MD
    Zhonghua Nei Ke Za Zhi; 2003 Jun; 42(6):382-7. PubMed ID: 12895320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus resistance to lamivudine and its clinical implications.
    Liu X; Schinazi RF
    Antivir Chem Chemother; 2002 May; 13(3):143-55. PubMed ID: 12448687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.
    Hacker HJ; Zhang W; Tokus M; Bock T; Schröder CH
    Ann N Y Acad Sci; 2004 Jun; 1022():271-81. PubMed ID: 15251972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamivudine for hepatitis B in clinical practice.
    Schiff ER
    J Med Virol; 2000 Jul; 61(3):386-91. PubMed ID: 10861651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
    Jarvis B; Faulds D
    Drugs; 1999 Jul; 58(1):101-41. PubMed ID: 10439933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of pre-core mutant chronic hepatitis B infection to lamivudine.
    Rizzetto M; Volpes R; Smedile A
    J Med Virol; 2000 Jul; 61(3):398-402. PubMed ID: 10861653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
    Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
    Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.